Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection

Abstract

Transplantation of insulin-producing cells derived from pluripotent stem cells represents a highly promising approach for the radical treatment of type 1 diabetes (T1D). Informed by a comprehensive understanding of fetal pancreatic development, directed differentiation protocol for generating pancreatic β cells from pluripotent stem cells has been established and has achieved considerable advances, enabling the production of mature, fully functional β cells that closely recapitulate the characteristics of native pancreatic β cells. Preclinical studies have shown that the transplantation of stem cell–derived islets (SC-islets) reverses hyperglycemia in both mouse and nonhuman primate models, with a favorable safety profile. Early-phase clinical trials have further corroborated the safety and efficacy of this approach, a subset of patients with long-standing T1D achieved insulin independence, described as a “functional cure”, with no serious adverse events of clinical significance reported. Despite these encouraging results, substantial challenges remain. With respect to differentiation protocols, insufficient functional maturity, pronounced cellular heterogeneity, significant batch-to-batch variability, and the challenges of large-scale manufacturing represent the principal unresolved limitations. Of particular concern, immune rejection remains a critical barrier even after the transplantation of autologous SC-islets, necessitating continued reliance on immunosuppressive therapy. Cell encapsulation and gene editing strategies have emerged as potential approaches to overcome this immunological barrier. In this review, we discuss strategies for obtaining insulin-producing cells from diverse cellular sources, summarize the latest advances in stem cell–based diabetes therapy, and propose future research directions.

Keywords

immune rejection / islet organoids / stem cell therapy / type 1 diabetes / β cells

References

[1] Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr. 2019; 13(1): 364-372.

[2] Hong Suna PS, Karuranga S. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119.

[3] Greenstein ELDAFJL. Navigating two roads to glucose normalization in diabetes: automated insulin delivery devices and cell therapy. Cell Metab. 2019; 29: 545-563.

[4] Grattoni A, Korbutt G, Tomei AA, et al. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead. Nat Rev Endocrinol. 2025; 21(1): 14-30.

[5] Chen S, Du K, Zou C. Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Res Ther. 2020; 11(1):275.

[6] Rickels MR, Robertson RP. Pancreatic islet transplantation in humans: recent progress and future directions. Endocr Rev. 2019; 40: 631-668.

[7] Bruin JE, Rezania A, Kieffer TJ. Replacing and safeguarding pancreatic beta cells for diabetes. Sci Transl Med. 2015; 7(316):316ps23.

[8] Ghoneim MA, Gabr MM, El-Halawani SM, Refaie AF. Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration. Stem Cell Res Ther. 2024; 15(1):23.

[9] Lemos JRN, Skyler JS. Challenges in beta cell replacement for type 1 diabetes. Horm Res Paediatr. 2025; 98(4): 435-449.

[10] Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes. 2001; 50(8): 1691-1697.

[11] Brolen GK, Heins N, Edsbagge J, Semb H. Signals from the embryonic mouse pancreas induce differentiation of human embryonic stem cells into insulin-producing beta-cell-like cells. Diabetes. 2005; 54(10): 2867-2874.

[12] Jennings RE, Berry AA, Kirkwood-Wilson R, et al. Development of the human pancreas from foregut to endocrine commitment. Diabetes. 2013; 62(10): 3514-3522.

[13] Pan FC, Brissova M. Pancreas development in humans. Curr Opin Endocrinol Diabetes Obes. 2014; 21(2): 77-82.

[14] Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 2001; 292(5520): 1389-1394.

[15] Segev H, Fishman B, Ziskind A, Shulman M, Itskovitz-Eldor J. Differentiation of human embryonic stem cells into insulin-producing clusters. Stem Cells. 2004; 22(3): 265-274.

[16] Hogrebe NJ, Maxwell KG, Augsornworawat P, Millman JR. Generation of insulin-producing pancreatic beta cells from multiple human stem cell lines. Nat Protoc. 2021; 16(9): 4109-4143.

[17] D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, Baetge EE. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol. 2005; 23(12): 1534-1541.

[18] Bruin JE, Erener S, Vela J, et al. Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Res. 2014; 12(1): 194-208.

[19] Jiang W, Shi Y, Zhao D, et al. In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Res. 2007; 17(4): 333-344.

[20] D'Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24(11): 1392-1401.

[21] Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008; 26(4): 443-452.

[22] Zhang D, Jiang W, Liu M, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009; 19(4): 429-438.

[23] Pagliuca FW, Millman JR, Gurtler M, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014; 159(2): 428-439.

[24] Rezania A, Bruin JE, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014; 32(11): 1121-1133.

[25] Yabe SG, Fukuda S, Takeda F, Nashiro K, Shimoda M, Okochi H. Efficient generation of functional pancreatic beta-cells from human induced pluripotent stem cells. J Diabetes. 2017; 9(2): 168-179.

[26] Nair GG, Liu JS, Russ HA, et al. Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived beta cells. Nat Cell Biol. 2019; 21(2): 263-274.

[27] Velazco-Cruz L, Song J, Maxwell KG, et al. Acquisition of dynamic function in human stem cell-derived beta cells. Stem Cell Rep. 2019; 12(2): 351-365.

[28] Du Y, Liang Z, Wang S, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat Med. 2022; 28(2): 272-282.

[29] Liu H, Li R, Liao HK, et al. Chemical combinations potentiate human pluripotent stem cell-derived 3D pancreatic progenitor clusters toward functional beta cells. Nat Commun. 2021; 12(1):3330.

[30] Balboa D, Barsby T, Lithovius V, et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat Biotechnol. 2022; 40(7): 1042-1055.

[31] Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006; 126(4): 677-689.

[32] Hogrebe NJ, Gooch KJ. Direct influence of culture dimensionality on human mesenchymal stem cell differentiation at various matrix stiffnesses using a fibrous self-assembling peptide hydrogel. J Biomed Mater Res A. 2016; 104(9): 2356-2368.

[33] Kilian KA, Bugarija B, Lahn BT, Mrksich M. Geometric cues for directing the differentiation of mesenchymal stem cells. Proc Natl Acad Sci USA. 2010; 107(11): 4872-4877.

[34] McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell. 2004; 6(4): 483-495.

[35] Ahn EH, Kim Y, Kshitiz , et al. Spatial control of adult stem cell fate using nanotopographic cues. Biomaterials. 2014; 35(8): 2401-2410.

[36] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, Millman JR. Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat Biotechnol. 2020; 38(4): 460-470.

[37] Bruin JE, Rezania A, Xu J, et al. Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia. 2013; 56(9): 1987-1998.

[38] Rezania A, Bruin JE, Riedel MJ, et al. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes. 2012; 61(8): 2016-2029.

[39] Rezania A, Bruin JE, Xu J, et al. Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells. 2013; 31(11): 2432-2442.

[40] Aigha II, Abdelalim EM. NKX6.1 transcription factor: a crucial regulator of pancreatic beta cell development, identity, and proliferation. Stem Cell Res Ther. 2020; 11(1):459.

[41] Al-Khawaga S, Memon B, Butler AE, Taheri S, Abou-Samra AB, Abdelalim EM. Pathways governing development of stem cell-derived pancreatic beta cells: lessons from embryogenesis. Biol Rev Camb Philos Soc. 2018; 93(1): 364-389.

[42] Zhang D, Jiang W, Shi Y, Deng H. Generation of pancreatic islet cells from human embryonic stem cells. Sci China C Life Sci. 2009; 52(7): 615-621.

[43] Nostro MC, Sarangi F, Yang C, et al. Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem Cell Rep. 2015; 4(4): 591-604.

[44] Memon B, Karam M, Al-Khawaga S, Abdelalim EM. Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1. Stem Cell Res Ther. 2018; 9(1):15.

[45] Memon B, Younis I, Abubaker F, Abdelalim EM. PDX1(−)/NKX6.1(+) progenitors derived from human pluripotent stem cells as a novel source of insulin-secreting cells. Diabetes Metab Res Rev. 2021; 37(5):e3400.

[46] Jiang Y, Chen C, Randolph LN, et al. Generation of pancreatic progenitors from human pluripotent stem cells by small molecules. Stem Cell Rep. 2021; 16(9): 2395-2409.

[47] Trott J, Tan EK, Ong S, et al. Long-term culture of self-renewing pancreatic progenitors derived from human pluripotent stem cells. Stem Cell Rep. 2017; 8(6): 1675-1688.

[48] Goncalves CA, Larsen M, Jung S, et al. A 3D system to model human pancreas development and its reference single-cell transcriptome atlas identify signaling pathways required for progenitor expansion. Nat Commun. 2021; 12(1):3144.

[49] Bakhti M, Scheibner K, Tritschler S, et al. Establishment of a high-resolution 3D modeling system for studying pancreatic epithelial cell biology in vitro. Mol Metab. 2019; 30: 16-29.

[50] Ma X, Lu Y, Zhou Z, et al. Human expandable pancreatic progenitor–derived β cells ameliorate diabetes. Sci Adv. 2022; 8:eabk1826.

[51] Navarro-Tableros V, Gomez Y, Brizzi MF, Camussi G. Generation of human stem cell-derived pancreatic organoids (POs) for regenerative medicine. Adv Exp Med Biol. 2020; 1212: 179-220.

[52] Kim Y, Kim H, Ko UH, et al. Islet-like organoids derived from human pluripotent stem cells efficiently function in the glucose responsiveness in vitro and in vivo. Sci Rep. 2016; 6:35145.

[53] Wang W, Jin S, Ye K. Development of islet organoids from H9 human embryonic stem cells in biomimetic 3D scaffolds. Stem Cells Dev. 2017; 26(6): 394-404.

[54] Yoshihara E, O'Connor C, Gasser E, et al. Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 2020; 586(7830): 606-611.

[55] Wang S, Du Y, Zhang B, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell. 2024; 187(22): 6152-6164 e18.

[56] Meng G, Gu J, Liew SY, et al. Reconstruction of endocrine subtype-complete human pluripotent stem cell-derived islets with capacity for hypoglycemia protection in vivo. Cell Stem Cell. 2025; 32(9): 1438-1456 e7.

[57] Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov. 2024; 10(1):45.

[58] Jun Y, Nguyen-Ngoc KV, Sai S, et al. Engineered vasculature induces functional maturation of pluripotent stem cell derived islet organoids. Dev Cell. 2025; 60(18): 2455-2469.e7.

[59] Citro A, Moser PT, Dugnani E, et al. Biofabrication of a vascularized islet organ for type 1 diabetes. Biomaterials. 2019; 199: 40-51.

[60] Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004; 429(6987): 41-46.

[61] Inada A, Nienaber C, Katsuta H, et al. Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci USA. 2008; 105(50): 19915-19919.

[62] Teta M, Rankin MM, Long SY, Stein GM, Kushner JA. Growth and regeneration of adult beta cells does not involve specialized progenitors. Dev Cell. 2007; 12(5): 817-826.

[63] Xu X, D'Hoker J, Stange G, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008; 132(2): 197-207.

[64] Wang D, Wang J, Bai L, et al. Long-term expansion of pancreatic islet organoids from resident Procr(+) progenitors. Cell. 2020; 180(6): 1198-1211 e19.

[65] Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 2008; 455(7213): 627-632.

[66] Li W, Cavelti-Weder C, Zhang Y, et al. Long-term persistence and development of induced pancreatic beta cells generated by lineage conversion of acinar cells. Nat Biotechnol. 2014; 32(12): 1223-1230.

[67] Li W, Nakanishi M, Zumsteg A, et al. In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypes. elife. 2014; 3:e01846.

[68] Liu G, Li Y, Li M, et al. Charting a high-resolution roadmap for regeneration of pancreatic beta cells by in vivo transdifferentiation from adult acinar cells. Sci Adv. 2023; 9(21):eadg2183.

[69] Furuyama K, Chera S, van Gurp L, et al. Diabetes relief in mice by glucose-sensing insulin-secreting human alpha-cells. Nature. 2019; 567(7746): 43-48.

[70] Kottaisamy CPD, Raj DS, Prasanth Kumar V, Sankaran U. Experimental animal models for diabetes and its related complications—a review. Lab Anim Res. 2021; 37(1):23.

[71] Chatzigeorgiou A, Halapas A, Kalafatakis K, Kamper E. The use of animal models in the study of diabetes mellitus. In Vivo. 2009; 23(2): 245-258.

[72] King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012; 166(3): 877-894.

[73] Pearson JA, Wong FS, Wen L. The importance of the non obese diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun. 2016; 66: 76-88.

[74] Crisa L, Mordes JP, Rossini AA. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab Rev. 1992; 8(1): 4-37.

[75] Yokoi N, Hayashi C, Fujiwara Y, Wang HY, Seino S. Genetic reconstitution of autoimmune type 1 diabetes with two major susceptibility genes in the rat. Diabetes. 2007; 56(2): 506-512.

[76] Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. New inbred strain of Long-Evans Tokushima lean rats with IDDM without lymphopenia. Diabetes. 1991; 40(11): 1375-1381.

[77] Lenzen S, Tiedge M, Elsner M, et al. The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia. 2001; 44(9): 1189-1196.

[78] Arndt T, Jorns A, Hedrich HJ, Lenzen S, Wedekind D. Variable immune cell frequencies in peripheral blood of LEW.1AR1-iddm rats over time compared to other congenic LEW strains. Clin Exp Immunol. 2014; 177(1): 168-178.

[79] Singh R, Gholipourmalekabadi M, Shafikhani SH. Animal models for type 1 and type 2 diabetes: advantages and limitations. Front Endocrinol (Lausanne). 2024; 15:1359685.

[80] Weiss H, Bleich A, Hedrich HJ, et al. Genetic analysis of the LEW.1AR1-iddm rat: an animal model for spontaneous diabetes mellitus. Mamm Genome. 2005; 16(6): 432-441.

[81] Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008; 51(2): 216-226.

[82] Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 2017; 53(6): 365-374.

[83] Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc. 2021; 1(4):e78.

[84] King A, Bowe J. Animal models for diabetes: understanding the pathogenesis and finding new treatments. Biochem Pharmacol. 2016; 99: 1-10.

[85] Al-Awar A, Kupai K, Veszelka M, et al. Experimental diabetes mellitus in different animal models. J Diabetes Res. 2016; 2016:9051426.

[86] Dufrane D, van Steenberghe M, Guiot Y, Goebbels RM, Saliez A, Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006; 81(1): 36-45.

[87] Yu M, Agarwal D, Korutla L, et al. Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes. Nat Metab. 2020; 2(10): 1013-1020.

[88] Peng X, Rao G, Li X, Tong N, Tian Y, Fu X. Preclinical models for type 1 diabetes mellitus—a practical approach for research. Int J Med Sci. 2023; 20(12): 1644-1661.

[89] Yamashita M, Adachi T, Adachi T, et al. Subcutaneous transplantation of engineered islet/adipose-derived mesenchymal stem cell sheets in diabetic pigs with total pancreatectomy. Regen Ther. 2021; 16: 42-52.

[90] Hu X, White K, Young C, et al. Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate. Cell Stem Cell. 2024; 31(3): 334-340 e5.

[91] Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest. 1983; 71(6): 1544-1553.

[92] Haller C, Piccand J, De Franceschi F, et al. Macroencapsulated human iPSC-derived pancreatic progenitors protect against STZ-induced hyperglycemia in mice. Stem Cell Rep. 2019; 12(4): 787-800.

[93] Harding JD. Nonhuman primates and translational research: progress, opportunities, and challenges. ILAR J. 2017; 58(2): 141-150.

[94] Harding J, Roberts RM, Mirochnitchenko O. Large animal models for stem cell therapy. Stem Cell Res Ther. 2013; 4(2):23.

[95] Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep. 2011; 11(5): 364-374.

[96] Liang Z, Sun D, Lu S, et al. Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets. Nat Metab. 2023; 5(1): 29-40.

[97] Henry RR, Pettus J, Wilensky JON, et al. Initial clinical evaluation of VC-01TM combination product—a stem cell–derived islet replacement for type 1 diabetes (T1D). Diabetes. 2018; 67(Supplement_1): 138-OR.

[98] Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 2021; 28(12): 2047-2061 e5.

[99] Shapiro AMJ, Thompson D, Donner TW, et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep Med. 2021; 2(12):100466.

[100] Keymeulen B, De Groot K, Jacobs-Tulleneers-Thevissen D, et al. Encapsulated stem cell-derived beta cells exert glucose control in patients with type 1 diabetes. Nat Biotechnol. 2024; 42(10): 1507-1514.

[101] Reichman TW, Markmann JF, Odorico J, et al. Stem cell-derived, fully differentiated islets for type 1 diabetes. N Engl J Med. 2025; 393(9): 858-868.

[102] Shi Y, Feng Y, Li T, et al. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant. Lancet Diabetes Endocrinol. 2026; 14(4): 285-288.

[103] Blau JE, Abegg MR, Flegel WA, Zhao X, Harlan DM, Rother KI. Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade. Am J Transplant. 2015; 15(11): 2995-3001.

[104] Ryan EA, Paty BW, Senior PA, Shapiro AM. Risks and side effects of islet transplantation. Curr Diab Rep. 2004; 4(4): 304-309.

[105] de Vos P, Hamel AF, Tatarkiewicz K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia. 2002; 45(2): 159-173.

[106] Fuchs S, Ernst AU, Wang LH, et al. Hydrogels in emerging technologies for type 1 diabetes. Chem Rev. 2021; 121(18): 11458-11526.

[107] Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2017; 16(5): 338-350.

[108] Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980; 210(4472): 908-910.

[109] Liu SS, Shim S, Kudo Y, et al. Encapsulated islet transplantation. Nat Rev Bioeng. 2024; 3(1): 83-102.

[110] Wu S, Wang L, Fang Y, Huang H, You X, Wu J. Advances in encapsulation and delivery strategies for islet transplantation. Adv Healthc Mater. 2021; 10(20):e2100965.

[111] Kizilel S, Garfinkel M, Opara E. The bioartificial pancreas: progress and challenges. Diabetes Technol Ther. 2005; 7(6): 968-985.

[112] Vaithilingam V, Bal S, Tuch BE. Encapsulated islet transplantation: where do we stand? Diab Stud. 2017; 14:51.

[113] Qi M. Transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus. Adv Med. 2014; 2014:429710.

[114] Song S, Faleo G, Yeung R, et al. Silicon nanopore membrane (SNM) for islet encapsulation and immunoisolation under convective transport. Sci Rep. 2016; 6:23679.

[115] Wang T. Successful diabetes management without immunosuppressivedrugs in NHP model has been demonstrated. Encapsulation system with taperednanopore conduits achieved normal glycaemia with regulated insulin release. Artif Cells Nanomed Biotechnol. 2018; 46(sup3): S1162-S1168.

[116] Bochenek MA, Veiseh O, Vegas AJ, et al. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat Biomed Eng. 2018; 2(11): 810-821.

[117] Orive G, Emerich D, Khademhosseini A, et al. Engineering a clinically translatable bioartificial pancreas to treat type I diabetes. Trends Biotechnol. 2018; 36(4): 445-456.

[118] Syed F, Bugliani M, Novelli M, et al. Conformal coating by multilayer nano-encapsulation for the protection of human pancreatic islets: in-vitro and in-vivo studies. Nanomedicine. 2018; 14(7): 2191-2203.

[119] Pathak S, Pham TT, Jeong JH, Byun Y. Immunoisolation of pancreatic islets via thin-layer surface modification. J Control Release. 2019; 305: 176-193.

[120] Song S, Roy S. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: cells, biomaterials, and devices. Biotechnol Bioeng. 2016; 113(7): 1381-1402.

[121] Elliott RB, Escobar L, Calafiore R, et al. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant Proc. 2005; 37(1): 466-469.

[122] Faleo G, Lee K, Nguyen V, Tang Q. Assessment of immune isolation of allogeneic mouse pancreatic progenitor cells by a macroencapsulation device. Transplantation. 2016; 100(6): 1211-1218.

[123] van Schilfgaarde R, de Vos P. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. J Mol Med (Berl). 1999; 77(1): 199-205.

[124] Ernst AU, Wang LH, Ma M. Islet encapsulation. J Mater Chem B. 2018; 6(42): 6705-6722.

[125] Fukuda S, Yabe SG, Nishida J, Takeda F, Nashiro K, Okochi H. The intraperitoneal space is more favorable than the subcutaneous one for transplanting alginate fiber containing iPS-derived islet-like cells. Regen Ther. 2019; 11: 65-72.

[126] Alagpulinsa DA, Cao JJL, Driscoll RK, et al. Alginate-microencapsulation of human stem cell-derived beta cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am J Transplant. 2019; 19(7): 1930-1940.

[127] Vegas AJ, Veiseh O, Gurtler M, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med. 2016; 22(3): 306-311.

[128] Wu DC, Boyd AS, Wood KJ. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells. 2008; 26(8): 1939-1950.

[129] Szot GL, Yadav M, Lang J, et al. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015; 16(2): 148-157.

[130] Deuse T, Hu X, Agbor-Enoh S, et al. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nat Biotechnol. 2019; 37(10): 1137-1144.

[131] Bogomiakova ME, Sekretova EK, Anufrieva KS, et al. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. Stem Cell Res Ther. 2023; 14(1):77.

[132] Masuda K, Kawamoto H. Possible NK cell-mediated immune responses against iPSC-derived cells in allogeneic transplantation settings. Inflamm Regen. 2021; 41(1):2.

[133] Mattapally S, Pawlik KM, Fast VG, et al. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. J Am Heart Assoc. 2018; 7(23):e010239.

[134] Sackett SD, Kaplan SJ, Mitchell SA, et al. Genetic engineering of immune evasive stem cell-derived islets. Transpl Int. 2022; 35:10817.

[135] Liu X, Li W, Fu X, Xu Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front Immunol. 2017; 8:645.

[136] Xu H, Wang B, Ono M, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019; 24(4): 566-578 e7.

[137] Thongsin N, Wattanapanitch M. CRISPR/Cas9 ribonucleoprotein complex-mediated efficient B2M knockout in human induced pluripotent stem cells (iPSCs). Methods Mol Biol. 2022; 2454: 607-624.

[138] Bogomiakova ME, Sekretova EK, Eremeev AV, et al. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing. Stem Cell Res. 2021; 55:102451.

[139] Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019; 37(3): 252-258.

[140] Han X, Wang M, Duan S, et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci USA. 2019; 116(21): 10441-10446.

[141] Gerace D, Zhou Q, Kenty JH, et al. Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep Med. 2023; 4(1):100879.

[142] Hu X, White K, Olroyd AG, et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol. 2024; 42(3): 413-423.

[143] Tsuneyoshi N, Hosoya T, Takeno Y, et al. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity. Stem Cell Res Ther. 2024; 15(1):193.

[144] Tam V, Wong NCM, Poon ACH, et al. Genome-edited safe and immune-evasive human pluripotent cells: potential solution for allogeneic therapies. Stem Cell Rep. 2026: 102850. Online ahead of print.

[145] Carlsson PO, Hu X, Scholz H, et al. Survival of transplanted allogeneic beta cells with no immunosuppression. N Engl J Med. 2025; 393(9): 887-894.

[146] Veres A, Faust AL, Bushnell HL, et al. Charting cellular identity during human in vitro beta-cell differentiation. Nature. 2019; 569(7756): 368-373.

[147] Cuesta-Gomez N, Verhoeff K, Jasra IT, Pawlick R, Dadheech N, Shapiro AMJ. Characterization of stem-cell-derived islets during differentiation and after implantation. Cell Rep. 2022; 40(8):111238.

[148] Diane A, Mu-U-Min RBA, Al-Siddiqi HH. Epigenetic memory as crucial contributing factor in directing the differentiation of human iPSC into pancreatic beta-cells in vitro. Cell Tissue Res. 2025; 399(3): 267-276.

[149] Dadheech N, Bermudez de Leon M, Czarnecka Z, et al. Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using vertical wheel(R) bioreactors. npj Regener Med. 2025; 10(1):24.

[150] Hua H, Wang Y, Wang X, et al. Remodeling ceramide homeostasis promotes functional maturation of human pluripotent stem cell-derived beta cells. Cell Stem Cell. 2024; 31(6): 850-865 e10.

[151] Mu-U-Min RBA, Diane A, Allouch A, Al-Siddiqi HH. Ca(2+)-mediated signaling pathways: a promising target for the successful generation of mature and functional stem cell-derived pancreatic beta cells in vitro. Biomedicine. 2023; 11(6):1577.

[152] Ma Z, Zhang X, Zhong W, et al. Deciphering early human pancreas development at the single-cell level. Nat Commun. 2023; 14(1):5354.

[153] Olaniru OE, Kadolsky U, Kannambath S, et al. Single-cell transcriptomic and spatial landscapes of the developing human pancreas. Cell Metab. 2023; 35(1): 184-199 e5.

[154] Augsornworawat P, Maxwell KG, Velazco-Cruz L, Millman JR. Single-cell transcriptome profiling reveals beta cell maturation in stem cell-derived islets after transplantation. Cell Rep. 2020; 32(8):108067.

[155] Augsornworawat P, Hogrebe NJ, Ishahak M, et al. Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification. Nat Cell Biol. 2023; 25(6): 904-916.

[156] Zhu H, Wang G, Nguyen-Ngoc KV, et al. Understanding cell fate acquisition in stem-cell-derived pancreatic islets using single-cell multiome-inferred regulomes. Dev Cell. 2023; 58(9): 727-743 e11.

[157] Madrid M, Sumen C, Aivio S, Saklayen N. Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges. Curr Protoc. 2021; 1(3):e88.

[158] de Klerk E, Hebrok M. Stem cell-based clinical trials for diabetes mellitus. Front Endocrinol (Lausanne). 2021; 12:631463.

[159] Hassanein A, Akhtar S. Recent advances in stem cell-based therapies for type 1 diabetes: a glimpse into the future. Biomol Biomed. 2025; 26(1): 5-23.

[160] Mu-U-Min RBA, Diane A, Allouch A, Al-Siddiqi HH. Immune evasion in stem cell-based diabetes therapy-current strategies and their application in clinical trials. Biomedicine. 2025; 13(2):383.

[161] Wang X, Zeng Z, Li D, et al. Advancements and challenges in immune protection strategies for islet transplantation. J Diabetes. 2025; 17(1):e70048.

[162] Kioulaphides S, Garcia AJ. Encapsulation and immune protection for type 1 diabetes cell therapy. Adv Drug Deliv Rev. 2024; 207:115205.

[163] Licht BJM, Duffy GP, Levey RE. Engineering hypoimmune stem cell-derived beta cells. Stem Cell Res Ther. 2025; 16(1):610.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.